Reviva Pharmaceuticals Announces One-for-Twenty Reverse Stock Split

An announcement from Reviva Pharmaceuticals Holdings ( (RVPH) ) is now available.

On March 4, 2026, Reviva Pharmaceuticals filed an amendment to its charter to implement a one-for-twenty reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on March 9, 2026, with shares to begin trading on a split-adjusted basis that day under a new CUSIP while preserving existing ownership percentages and adjusting all derivative securities accordingly. The move follows shareholder authorization in December 2025 and board approval on February 26, 2026, and is aimed at helping the company regain compliance with Nasdaq’s $1.00 minimum bid price rule after it received deficiency and delisting notices in 2025 and secured an exception through March 27, 2026, though Reviva warns the split may not sustainably lift its share price and that delisting would materially hurt liquidity and its ability to raise capital.

The company disclosed that failure to meet Nasdaq’s continued listing requirements, including the minimum bid price, could result in delisting, which would likely depress its stock price, reduce trading liquidity, and impair access to financing and business opportunities. Reviva also noted that the reduced share count after the reverse split could negatively impact trading liquidity and market capitalization, and that the Nasdaq Hearings Panel retains discretion to reconsider the listing exception if circumstances change, leaving investors exposed to ongoing listing and valuation risks.

The most recent analyst rating on (RVPH) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Reviva Pharmaceuticals Holdings stock, see the RVPH Stock Forecast page.

Spark’s Take on RVPH Stock

According to Spark, TipRanks’ AI Analyst, RVPH is a Neutral.

The score is driven primarily by weak financial fundamentals (no revenue, sizable losses, and ongoing cash burn with reliance on future funding). Technicals also reflect a downtrend with negative momentum. Corporate events add material near-term risk (Nasdaq compliance/delisting pressure and extended regulatory timeline requiring additional financing).

To see Spark’s full report on RVPH stock, click here.

More about Reviva Pharmaceuticals Holdings

Reviva Pharmaceuticals Holdings, Inc. is a biopharmaceutical company whose common stock trades on the Nasdaq Capital Market under the symbol RVPH. The company operates in the pharmaceutical sector and relies on continued access to public equity markets, making compliance with Nasdaq listing standards critical to its capital-raising efforts and investor base.

Average Trading Volume: 5,050,404

Technical Sentiment Signal: Sell

Current Market Cap: $24.77M

For an in-depth examination of RVPH stock, go to TipRanks’ Overview page.